Securities code: 000806 securities abbreviation: Galaxy Biomedical Investment Co.Ltd(000806) Announcement No.: 2022-005
Galaxy Biomedical Investment Co.Ltd(000806)
Announcement on receipt of notice of assignment of creditor’s rights and notice of debt collection
The company and all members of the board of directors guarantee that the information disclosed is true, accurate and complete without false records, misleading statements or major omissions.
Galaxy Biomedical Investment Co.Ltd(000806) (hereinafter referred to as “the company”) has recently received the notice of creditor’s right transfer issued by Shenzhen SDIC Supply Chain Management Co., Ltd. (hereinafter referred to as “SDIC supply chain”) and the notice of debt collection issued by Suzhou hanzhan Enterprise Management Co., Ltd. (hereinafter referred to as “Suzhou hanzhan”), and the relevant information is hereby announced as follows:
1、 Main contents of the notice of assignment of creditor’s rights and the notice of debt collection
(1) Main contents of the notice of assignment of creditor’s rights:
SDIC supply chain signed the creditor’s rights transfer contract with Suzhou hanzhan, and has transferred the creditor’s rights to the company based on (2020) yueminzhong No. 1599 civil judgment to Suzhou hanzhan. Inform our company to fulfill the debts to be borne under the civil judgment (2020) yueminzhong No. 1599 to Suzhou hanzhan from the date of receiving the notice.
(2) Main contents of debt collection notice:
Suzhou hanzhan has legally accepted the creditor’s rights against the company under the civil judgment (2020) yueminzhong No. 1599 of Guangdong Higher People’s court transferred by the SDIC supply chain, and informed the company that if the company can take the initiative to perform its debt obligations under the civil judgment (2020) yueminzhong No. 1599, it agrees to exempt the company from the interest, penalty interest Late fees and other related derivative expenses.
2、 Impact on the company and other information
1. The creditor’s right has been finally adjudicated by the higher people’s Court of Guangdong Province and has come into force (see the announcement on litigation progress disclosed by the company, announcement numbers: 2019-021, 2020-016 and 2021-098). The transfer of the creditor’s rights resulted in the change of the company’s creditors.
2. The information disclosure media designated by the company are securities times, securities daily and cninfo（ http://www.cn.info.com.cn. ）, the relevant information of the company is published on the above designated information disclosure media
The announcement of the company shall prevail. Please pay attention to the relevant announcements of the company, make rational investment and pay attention to investment risks. It is hereby announced.
Galaxy Biomedical Investment Co.Ltd(000806) board of directors
January 20, 2002
